Edoardo Sciatti,Emilia D&#x;Elia,Mauro Gori et al.
Edoardo Sciatti et al.
Cardiac glycosides represent one of the oldest therapeutic pillars in medicine, although their role has progressively diminished in the modern era of neurohormonal therapy for heart failure (HF). Following publication of the Digitalis Inves...
Filippo Stazi
Filippo Stazi
Despite the use of oral anticoagulants, the residual risk of recurrent ischaemic stroke in patients with atrial fibrillation (AF) is ∼4% per year; however, in patients who experience a stroke despite oral anticoagulant therapy (OAT), this ...
Early discontinuation of acetylsalicylic acid after angioplasty in acute coronary syndromes: the NEO-MINDSET and TARGET-FIRST studies [0.03%]
急性冠脉综合征患者血管成形术后早期停用阿司匹林：NEO-MINDSET和TARGET-FIRST研究
Giacinto Di Leo,Diego Nastasi,Davide Capodanno
Giacinto Di Leo
Dual antiplatelet therapy (DAPT) with acetylsalicylic acid (ASA) and a P2Y12 receptor inhibitor (P2Y12i) for 12 months represents the standard of care after acute coronary syndrome (ACS). However, balancing ischaemic protection against blee...
New cardiovascular risk factor and clinical surrogate: epicardial fat [0.03%]
新的心血管风险因素和临床替代标志物：心外膜脂肪组织
Saima Mushtaq,Maria Elisabetta Mancini,Riccardo Maragna et al.
Saima Mushtaq et al.
Coronary computed tomography angiography (CCTA) has become a cornerstone in the non-invasive evaluation of coronary artery disease (CAD). Beyond defining stenosis severity, CCTA enables detailed quantification of total atherosclerotic burde...
How difficult is the diagnosis of heart failure with preserved ejection fraction [0.03%]
射血分数保留的心力衰竭诊断难度如何
Andrea Cesari,Alice Sacco,Fabrizio Giovanni Oliva
Andrea Cesari
Heart failure with preserved ejection fraction (HFpEF) is a systemic syndrome driven by inflammation, with a substantial contribution from comorbidities, ageing, lifestyle factors, and genetic predisposition. Heart failure with preserved ej...
Francesco Prati,Andrea Giovagnoli,Giulia Paoletti et al.
Francesco Prati et al.
The widespread use of coronary computed tomography (CT) to exclude significant coronary stenoses and, more broadly, to achieve a more accurate assessment of cardiovascular risk through the evaluation of atherosclerosis has gained momentum i...
Discontinuation of anticoagulation therapy after atrial fibrillation ablation: the ALONE-AF and OCEAN studies [0.03%]
心房颤动射频消融术后抗凝治疗的停药问题——ALONE-AF和OCEAN研究
Mario Campisi,Florinda Bonanno,Piera Capranzano
Mario Campisi
Two randomized trials, the ALONE-AF and OCEAN, have provided valuable evidence to guide the management of oral anticoagulation therapy after ablation of atrial fibrillation. In the ALONE-AF study, amongst patients with no documented atrial ...
Alberto Aimo,Vincenzo Castiglione,Luna Latorre et al.
Alberto Aimo et al.
Transthyretin amyloidosis (ATTR) is a systemic disease characterized by the deposition of misfolded transthyretin (TTR) fibrils. It most commonly presents as cardiomyopathy (ATTR-CM), particularly in elderly patients with the wild-type form...
Mitral Valve Prolapse Associated with Mitral Annular Disjunction: Diagnosis, Prognosis, and Arrhythmic Risk [0.03%]
二尖瓣环脱垂伴二尖瓣环离断的诊断、预后及心律失常风险
Martina Perazzolo Marra,Cristina Basso
Martina Perazzolo Marra
Mitral valve prolapse (MVP) is the most common valvular heart disease, with a reported prevalence of 2-3% in the general population, and represents the leading structural cause of mitral regurgitation in Western countries. MVP has long been...
Moderate mitral regurgitation: when to prefer clip over medical therapy [0.03%]
中度二尖瓣反流：夹合术优于药物治疗的指征
Federica Coletti,Myriam Carpenito,Lorenzo Guarino et al.
Federica Coletti et al.
Functional mitral regurgitation (FMR) is common in patients with heart failure (HF) and is associated with an adverse prognosis. Therefore, both ventricular and atrial phenotypes of FMR represent relevant therapeutic targets in clinical pra...